Neuroprotective Doses of N‐Methyl‐D‐Aspartate Receptor Antagonists Profoundly Reduce the Minimum Alveolar Anesthetic Concentration (MAC) for Isoflurane in Rats

N-methyl-D-aspartate (NMDA) receptor antagonists, which block one of the glutamate receptors, have provided evidence of cerebral protection in animal models of focal cerebral ischemia. We examined the effect of neuroprotective doses of one noncompetitive (dizocilpine) and two competitive (D-CPP-ene, CGS 19755) NMDA antagonists on the minimum alveolar anesthetic concentration (MAC) of isoflurane in rats. A single bolus injection of any of the three NMDA antagonists produced a significant (P < 0.01) and sustained (>3 h) decrease in the MAC of isoflurane. Dizocilpine decreased MAC by 33%-38% at a dose of 0.15 mg/kg and 48%-54% at a dose of 0.5 mg/kg. D-CPPene decreased MAC by 32%-37% at a dose of 1.5 mg/kg and 39%-45% at a dose of 4.5 mg/kg. CGS 19755 decreased MAC by 19%-24% at a dose of 3 mg/kg and 49%-58% at a dose of 10 mg/kg. Dizocilpine, but not the competitive antagonists, produced a small transient decrease in mean arterial blood pressure. The sustained anesthetic potency of neuroprotective doses of NMDA antagonists supports the idea that glutaminergic receptor activity is involved in determining the anesthetic state.

[1]  R. Bullock,et al.  Evaluation of a competitive NMDA antagonist (D‐CPPene) in feline focal cerebral ischemia , 1991, Annals of neurology.

[2]  D. Choi Methods for antagonizing glutamate neurotoxicity. , 1990, Cerebrovascular and brain metabolism reviews.

[3]  A. Asbury,et al.  An evaluation of the Datex Normac anaesthetic agent monitor , 1986, Anaesthesia.

[4]  J. Mcculloch,et al.  The glutamate antagonist MK‐801 reduces focal ischemic brain damage in the rat , 1988, Annals of neurology.

[5]  D. Attwell,et al.  The release and uptake of excitatory amino acids. , 1990, Trends in pharmacological sciences.

[6]  B. Bean,et al.  Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Simon,et al.  N‐Methyl‐D‐Aspartate antagonist reduces stroke size and regional glucose metabolism , 1990, Annals of neurology.

[8]  M. Zornow,et al.  The noncompetitive N-methyl-d-aspartate receptor antagonist, MK-801 profoundly reduces volatile anesthetic requirements in rabbits , 1989, Neuropharmacology.

[9]  J. Woods,et al.  Analgesic, anesthetic, and respiratory effects of the competitiveN-methyl-d-aspartate (NMDA) antagonist CGS 19755 in rhesus monkeys , 1990, Brain Research.

[10]  D. Graham,et al.  Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. , 1990, Stroke.

[11]  H. Jacob,et al.  Cardiovascular Effects of the N‐Methyl‐D‐Aspartate Receptor Antagonist MK‐801 in Conscious Rats , 1989, Hypertension.

[12]  D. Graham,et al.  Focal Cerebral Ischemia in the Cat: Pretreatment with a Competitive NMDA Receptor Antagonist, D-CPP-ene , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  J. Mcculloch,et al.  Journal of Cerebral Blood Flow and Metabolism Effects of Mk-801 upon Local Cerebral Glucose Utilisation in Conscious Rats and in Rats Anaesthetised with Halothane , 2022 .

[14]  J. Olney,et al.  Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. , 1989, Science.

[15]  J. Mcculloch,et al.  Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose use , 1989, Brain Research.

[16]  Bradley V. Clineschmidt,et al.  Central sympathomimetic activity of (+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo [a, d]cyclohepten‐5,10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties , 2022 .

[17]  E. Mackenzie,et al.  The pharmacotherapy of focal cortical ischaemia in the mouse , 1990, Brain Research.

[18]  A. Chapman Excitatory amino acid antagonists and the therapy of epilepsy , 1992 .

[19]  P. White,et al.  Ketamine--its pharmacology and therapeutic uses. , 1982, Anesthesiology.

[20]  L. C. Daniell,et al.  The noncompetitive N-methyl-D-aspartate antagonists, MK-801, phencyclidine and ketamine, increase the potency of general anesthetics , 1990, Pharmacology Biochemistry and Behavior.

[21]  E. Wong,et al.  Non-competitive antagonists of excitatory amino acid receptors , 1987, Trends in Neurosciences.

[22]  J. Kemp,et al.  The neuroprotective action of dizocilpine (MK‐801) in the rat middle cerebral artery occlusion model of focal ischaemia , 1991, British journal of pharmacology.

[23]  D. Graham,et al.  Protective Effect of the Glutamate Antagonist, MK-801 in Focal Cerebral Ischemia in the Cat , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  S. Grillner,et al.  Excitatory amino acids and synaptic transmission: the evidence for a physiological function. , 1990, Trends in pharmacological sciences.

[25]  E. Eger,et al.  Determination and applications of MAC. , 1980, Anesthesiology.

[26]  R. Mazze,et al.  Halothane, isoflurane, and enflurane MAC in pregnant and nonpregnant female and male mice and rats. , 1985, Anesthesiology.